Overall Risk of Myopericarditis Low After COVID-19 Vaccine
Myopericarditis is rare following COVID-19 vaccination, with an overall incidence not differing significantly for those receiving COVID-19 vaccines or non-COVID-19 vaccines.
COVID19 Vaccine
BNT162b2 Prevents Critical COVID-19 in Children and Adolescents
For adolescents, vaccination provided protection against critical COVID-19 during omicron predominance, but provided lower protection against omicron-associated hospitalization.
COVID-19 Vaccination Early in Pregnancy Not Linked to Fetal Anomalies
COVID-19 vaccination within the teratogenic window (30 days before conception until 14 weeks of gestation) is not associated with increased odds of major fetal structural anomalies.
Is Tinnitus a Rare Side Effect Linked to SARS-CoV-2 Vaccination?
In a review, researchers evaluated any otologic manifestation following vaccine administration and investigated the potential pathophysiology, clinical approach, and treatment.
Fourth Dose of BNT162b2 Offers Protection Against Severe COVID-19
The rates of confirmed severe acute respiratory syndrome coronavirus 2 infection and severe COVID-19 were lower after receipt of a fourth dose of BNT162b2 vaccine.
FDA Advisers Weigh COVID-19 Booster Shots for Fall
Outlining a daunting timeline for development of any updated COVID-19 vaccine for next fall, federal health officials told an expert advisory panel that clinical trials of potential candidates would have to begin by next month, and a final formula chosen by June, to meet that tight deadline.
Vaccination Offers Extra Protection After SARS-CoV-2 Infection
Vaccination provides additional protection among those with immunity from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
Efficacy of COVID-19 Vaccination Significantly Differs by Immunocompromised Condition
Researchers performed a meta-analysis that assessed seroconversion rates associated with COVID-19 vaccination among patients with immunocompromised conditions.
Moderna Asks FDA to Approve Second Booster for All Adults
Moderna said that it has asked the US Food and Drug Administration to approve the emergency use of a second booster of its COVID-19 vaccine for all adults.
COVID-19 Vaccines Not Tied to Immune-Mediated Neurological Events
No safety signal is observed between COVID-19 vaccines and immune-mediated neurological events, but infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is associated with increased risks for Bell palsy, encephalomyelitis, and Guillain-Barré syndrome.
- Loading...
Loading...
Next post in General Neurology
Loading... 
Loading...